Moderna lifts COVID-19 vaccine sales forecast to $19.2 billion

Moderna Inc raised its 2021 sales forecast for its COVID-19 shot by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid vaccine rollouts.

>>Reuters
Published : 6 May 2021, 01:00 PM
Updated : 6 May 2021, 01:00 PM

Deals for "booster" doses, nations looking to stock up supplies for 2022 and beyond and a likely authorization for use of the vaccines in kids have led Moderna and its larger rival Pfizer to ramp up their supplies. Moderna said an initial analysis of a study in adolescents aged 12-17 years showed an efficacy rate of 96% for its vaccine.

The company has also been working on a new version that could extend the time the vaccine can be stored in refrigerator temperatures, making it easier to distribute, especially in lower-income countries.

However, Moderna shares along with other global vaccine makers fell in premarket trading following US President Joe Biden's decision to support a waiver of intellectual property rights for COVID-19 vaccines.

While the move is aimed at increasing vaccine availability in poorer countries, it could potentially hit sales of COVID-19 vaccines.

Chief Executive Stéphane Bancel said the company could sign more deals with countries for supply of the vaccine in 2022 than in 2021.

Earlier this week, Pfizer raised its full-year forecast for the COVID-19 vaccine it developed with Germany's BioNTech to $26 billion.

Moderna had in February forecast vaccine sales of $18.4 billion. In the first quarter ended March 31, its vaccine brought in sales of $1.7 billion, helping the drugmaker record a profit for the first time ever.

The company said it plans to file for full approval of the vaccine in the United States this month.